LFCR on Nasdaq

LIFECORE BIOMEDICAL, INC. \DE\

American pharmaceutical preparations company, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

$128.9MRevenue, fiscal 20252
-$38.7MNet income, fiscal 20252

Compare with Xencor Inc, ASCENTAGE PHARMA GROUP INTERNATIONAL or GYRE THERAPEUTICS, INC., or pick any stock.

  • TickerLFCR on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersDE
  • Incorporated inDE3
  • Business address3515 Lyman Boulevard, Chaska, Mn 553183
  • Filer categoryAccelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

31.3%Gross margin2
-13.4%Operating margin2
-30.0%Net margin2
0.5%Revenue growth, 20252
-2898.0%Return on equity2
97.63×Debt to equity2
-$13.6MFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Contract Development and Manufacturing Organization brought in 70% of the revenue LIFECORE BIOMEDICAL, INC. \DE\ broke down this way in fiscal 2025.

  1. Contract Development and Manufacturing Organization$90.1M470%down 7% from 2024
  2. HA Manufacturing$38.8M430%up 23% from 2024
Products and services by year
Products and services20242025
Contract Development and Manufacturing Organization$96.6M$90.1M
HA Manufacturing$31.6M$38.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue63¢$88.6M
  • Research and development6¢$8.3M
  • Selling, general and admin31¢$44.0M
  • Income tax0¢$43.0K

Out of $128.9M in revenue.2 The company lost money this year.

Financial statements

Revenue56782$128.9M in 2025−75% since 2018
0$200.0M$400.0M$600.0M2018: $524.2M$524.2M20182019: $557.6M$557.6M2019+6%2020: $160.1M$160.1M2020−71%2021: $100.9M$100.9M2021−37%2022: $111.3M$111.3M2022+10%2023: $103.3M$103.3M2023−7%2024: $128.3M$128.3M2024+24%2025: $128.9M$128.9M2025+0%
Gross profit9106782$40.3M in 2025−49% since 2018
0$25.0M$50.0M$75.0M$100.0M2018: $78.3M$78.3M20182019: $81.0M$81.0M2019+3%2020: $39.4M$39.4M2020−51%2021: $38.9M$38.9M2021−1%2022: $39.1M$39.1M2022+0%2023: $28.0M$28.0M2023−28%2024: $41.9M$41.9M2024+50%2025: $40.3M$40.3M2025−4%
Operating income9106782-$17.2M in 2025
-$30.0M-$20.0M-$10.0M0$10.0M$20.0M2018: $13.6M$13.6M20182019: $5.5M$5.5M2019−60%2020: -$25.9M-$25.9M20202021: -$8.8M-$8.8M2021−66%2022: -$11.8M-$11.8M2022+34%2023: -$21.8M-$21.8M2023+85%2024: -$8.8M-$8.8M2024−59%2025: -$17.2M-$17.2M2025+95%
Net income9106782-$38.7M in 2025
-$150.0M-$100.0M-$50.0M0$50.0M2018: $24.8M$24.8M20182019: $411.0K$411.0K2019−98%2020: -$38.2M-$38.2M20202021: -$32.3M-$32.3M2021−15%2022: -$116.7M-$116.7M2022+261%2023: -$99.6M-$99.6M2023−15%2024: $12.0M$12.0M20242025: -$38.7M-$38.7M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-05-312024-05-31
Revenues$128.9M$128.3M
Cost of sales$88.6M$86.4M
Gross profit$40.3M$41.9M
Research and development expenses$8.3M$8.6M
Selling, general, and administrative expenses$44.0M$40.5M
Loss on sale or disposal of assets, net of portion classified as cost of sales$7.0M$0
Restructuring (recovery) costs-$1.7M$1.7M
Operating loss-$17.2M-$8.8M
Interest income$333.0K$58.0K
Change in fair value of debt derivative liability, related party$409.0K$39.5M
Other income (expense), net-$3.0K-$3.1M
(Loss) income from continuing operations before income taxes-$38.7M$9.5M
Income tax expense-$43.0K-$183.0K
(Loss) income from continuing operations-$38.7M$9.3M
Income from discontinued operations$0$2.7M
Net (loss) income-$38.7M$12.0M
Preferred stock dividends-$3.3M$0
Accretion of preferred stock to redemption value-$192.0K$0
Fair value of conversion ratio improvement to preferred stockholders-$2.1M$0
(Loss) income available to common stockholders-$44.4M$12.0M
(Loss) income from continuing operations available to common stockholders (in dollars per share)-$1$0
Income from discontinued operations (in dollars per share)$0$0
Basic (loss) income per share (in dollars per share)-$1.27$0.39
(Loss) income from continuing operations available to common stockholders (in dollars per share)-$1$0
Income from discontinued operations (in dollars per share)$0$0
Diluted (loss) income per share (in dollars per share)-$1.27$0.33
Basic (in shares)34.8M shares30.5M shares
Diluted (in shares)34.8M shares36.7M shares

Compare LIFECORE BIOMEDICAL, INC. \DE\ with another company

Leadership

Who has led LIFECORE BIOMEDICAL, INC. \DE\, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gary T. Steele2006–2015
  2. Dennis J. Allingham2010
  3. Molly Hemmeter2016–2019
  4. Albert D. Bolles2019–2022
  5. Paul Josephs2024–now

President

  1. Gary T. Steele2006–2015
  2. Dennis J. Allingham2010

Chief financial officer

  1. Gregory S. Skinner2006–2020
  2. John D. Morberg2021–2024
  3. Ryan David Lake2024–now

Chief operating officer

  1. David D. Taft2006–2010
  2. Molly Hemmeter2014–2015
2010201520202025
Board members and other officers (36)

Former names

  • LANDEC CORP \CA\Jun 17, 1996 to Nov 7, 20223

Timeline

  1. May 22, 2024New chief executive Paul Josephs becomes CEO15
  2. May 28, 2019New chief executive Albert D. Bolles becomes CEO16
  3. Mar 24, 2016New chief executive Molly Hemmeter becomes CEO17
  4. May 27, 2010New chief executive Dennis J. Allingham becomes CEO18
  5. Jan 18, 2006New chief executive Gary T. Steele becomes CEO19

Filings

329 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 84 major events, 129 insider forms, 45 large holders, 49 other. The latest 20:

  1. Sep 29, 2026SCHEDULE 13D/A EDGAR
  2. Sep 29, 20268-K EDGAR
  3. Sep 28, 2026DEFA14A DEFA 14A EDGAR
  4. Sep 28, 20268-K EDGAR
  5. Sep 28, 2026SCHEDULE 13D/A EDGAR
  6. Aug 5, 202610-Q EDGAR
  7. Aug 5, 20268-K EDGAR
  8. Jul 29, 2026SCHEDULE 13G EDGAR
  9. Jul 2, 2026SCHEDULE 13D/A EDGAR
  10. Jul 2, 20268-K EDGAR
  11. Jul 2, 2026SCHEDULE 13D/A EDGAR
  12. Jun 8, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Jun 5, 20264 EDGAR
  14. Jun 5, 20264 EDGAR
  15. Jun 5, 20264 EDGAR
  16. Jun 5, 20264 EDGAR
  17. Jun 5, 20264 EDGAR
  18. Jun 5, 20264 EDGAR
  19. Jun 5, 20264 EDGAR
  20. Jun 5, 20268-K EDGAR

The 329 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 45 such filings since October 2021, the latest 10:

  1. Sep 29, 2026SCHEDULE 13D/A
  2. Sep 28, 2026SCHEDULE 13D/A
  3. Jul 29, 2026SCHEDULE 13G
  4. Jul 2, 2026SCHEDULE 13D/A
  5. Jul 2, 2026SCHEDULE 13D/A
  6. Apr 27, 2026SCHEDULE 13G/A
  7. Jan 21, 2026SCHEDULE 13G
  8. Oct 17, 2025SCHEDULE 13G/A
  9. May 29, 2025SCHEDULE 13D/A
  10. Feb 14, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 97. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Wynnefield Capital Inc4,703,216$24.7M17.0%No change
Legion Partners Asset Management, LLC4,461,823$23.4M57.8%No change
Greenhaven Road Investment Management, L.P.3,190,769$16.8M10.9%−346,804
325 Capital LLC2,895,881$15.2M3.6%+733,415
BlackRock, Inc.2,013,093$10.6M0.0%+135,788
Vanguard Capital Management LLC1,288,621$6.8M0.0%−1,515
Geode Capital Management, LLC855,500$4.5M0.0%+40,393
Morgan Stanley769,360$4.0M0.0%+4,626
State Street Corp668,031$3.5M0.0%+26,025
Quinn Opportunity Partners LLC453,495$2.4M0.1%No change
DCF Advisers, LLC424,500$2.2M0.6%No change
Wittenberg Investment Management, Inc.314,015$1.6M0.6%+12,200
Northern Trust Corp253,817$1.3M0.0%+25,659
Vanguard Fiduciary Trust Co239,924$1.3M0.0%+2,859
LPL Financial LLC207,300$1.1M0.0%−490
Vanguard Portfolio Management LLC189,073$992.6K0.0%+24,513
Marshall Wace, Llp177,471$931.7K0.0%+119,117
Tocqueville Asset Management L.P.151,700$796.4K0.0%No change
Millennium Management LLC133,305$699.9K0.0%−23,852
Goldman Sachs Group Inc124,940$655.9K0.0%−43,436
Renaissance Technologies LLC104,859$550.5K0.0%New
Grizzlyrock Capital, LLC103,000$540.8K0.4%−724,488
Citadel Advisors LLC98,870$519.1K0.0%New
Allspring Global Investments Holdings, LLC96,589$509.0K0.0%New
Squarepoint Ops LLC92,674$486.5K0.0%+40,270

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56